ライフサイエンスコーパス: ocular surface disease

1 was given to measure subjective symptoms of ocular surface disease.

2 for patients presenting with periorbital and ocular surface disease.

3 d goblet cell mucin secretion into tears and ocular surface disease.

4 f wound stability, intraocular fluidics, and ocular surface disease.

5 tory use will strengthen our arsenal against ocular surface disease.

6 rigid gas-permeable lenses in the therapy of ocular surface disease.

7 s damage of the ocular surface epithelium in ocular surface disease.

8 mice, which provide unique models of severe ocular surface disease.

9 ibute to susceptibility to lacrimal gland or ocular surface disease.

10 lenses were collected from patients with no ocular surface disease.

11 id not have preoperative dry eye syndrome or ocular surface disease.

12 is a chronic, sight-threatening inflammatory ocular surface disease.

13 bsent ENaC function in the MG and associated ocular surface disease.

14 ronmental characteristics in the etiology of ocular surface disease.

15 or serious ophthalmic complications owing to ocular surface disease.

16 developed treatment for patients with severe ocular surface disease.

17 of scleral lens therapy in the management of ocular surface disease.

18 used in the management of moderate to severe ocular surface disease.

19 ropriate treatment, and better management of ocular surface disease.

20 Tear film stability is the key event in ocular surface diseases.

21 nctival epithelium in drying and cicatrizing ocular surface diseases.

22 apeutic target for allergic and inflammatory ocular surface diseases.

23 many potential interventional therapies for ocular surface diseases.

24 cy of doxycycline in treating MMP-9-mediated ocular surface diseases.

25 us serum and RA application in patients with ocular surface diseases.

26 oic acid (RA) have been used to treat drying ocular surface diseases.

27 esis of sterile corneal ulceration and other ocular surface diseases.

28 and doxycycline, a medication used to treat ocular surface diseases.

29 entifying clinically relevant biomarkers for ocular surface diseases.

30 accine and therapeutic development for other ocular surface diseases.

31 ption for visual rehabilitation in end-stage ocular surface diseases.

32 discuss recent advances in MSC for treating ocular surface diseases.

33 ment for patients with end-stage corneal and ocular surface diseases.

34 history of infectious keratitis (19.3%), and ocular surface disease (16.1%).

35 eusis in situ (2 eyes), and undifferentiated ocular surface disease (4 eyes).

36 Patients with yeast keratitis had more ocular surface disease (79% vs 28%) while patients with

37 OOKP procedures were performed for severe ocular surface disease according to the indications and

38 Many of these syndromes can lead to ocular surface disease and are becoming more prevalent a

39 ew and update on recent literature regarding ocular surface disease and corneal refractive surgery.

40 ing body of research that links androgens to ocular surface disease and DED.

41 f ocular neuropathic pain despite absence of ocular surface disease and failing to identify exposure

42 tear film and tear production abnormalities, ocular surface disease and inflammation, and corneal abn

43 Ocular surface disease and its complications were associ

44 Patients with APS-1 may have ocular surface disease and severe damage to corneal nerv

45 Rapid blinking is associated with worse ocular surface disease and tear stability.

46 Studies involving ocular surface disease and/or keratorefractive (corneal)

47 urrent research on the microbiome of various ocular surface diseases and how these findings may impac

48 gh-risk adult patients, including those with ocular surface diseases and multiple graft rejections, a

49 sented with intraocular inflammation, 2 with ocular surface disease, and 1 with orbital myopathy.

50 d with greater irritation, tear instability, ocular surface disease, and blink rate.

51 d tear production, accelerated tear breakup, ocular surface disease, and immunopathologic response.

52 hthalmos is an often-overlooked component of ocular surface disease, and its prevalence is likely on

53 -negative ulcers, viral etiology, coexistent ocular surface disease, and multiple grafts were exclude

54 tuberculin skin test status, the presence of ocular surface disease, and the anatomic relationship be

55 ast hope for restoration of vision in severe ocular surface disease, and the retinal surgeon is frequ

56 Glaucoma is associated with significant ocular surface disease, and topical glaucoma therapy bur

57 VR)-induced skin pigmentation, skin cancers, ocular surface disease, and, in some patients, sunburn a

58 nstruments for DE and clinician diagnoses of ocular surface diseases, and perform a classification in

59 ta-thalassemia ocular manifestations include ocular surface disease, as demonstrated by tear function

60 a useful model to examine exocrinopathy and ocular surface disease associated with SS.

61 ted therapies may be beneficial for treating ocular surface disease associated with SS.

62 91 among patients with end-stage corneal and ocular surface diseases at an additional cost of S$67 84

63 The current trend is to diagnose and treat ocular surface disease before cataract surgery using a s

64 r scleral lens therapy for the management of ocular surface disease between June 1, 2006, and Novembe

65 ficial not only in patients with established ocular surface disease, but also in those with minimal s

66 She was diagnosed with severe NK and ocular surface disease caused by dry eye.

67 es, such as Meckel syndrome, present several ocular surface disease conditions of unclear pathogenesi

68 onor eyes developed any clinical features of ocular surface disease, conjunctival overgrowth of the d

69 f AD patients develop a dupilumab-associated ocular surface disease (DAOSD), of which the pathomechan

70 In all patients, vision-threatening ocular surface disease developed as a result of chronic

71 eater proportion of eyes with autoimmune and ocular surface diseases developed de novo glaucoma after

72 Ocular surface disease due to an autoimmune cause demons

73 r scleral lens therapy were undifferentiated ocular surface disease, exposure keratopathy, and neurot

74 r graft failure (corneal neovascularization, ocular surface disease, glaucoma, active corneal inflamm

75 tative markers of eyelid laxity or secondary ocular surface disease in a sleep clinic population.

76 ible role in the development of exocrine and ocular surface disease in Aire knockout mice.

77 rategies for the diagnosis and management of ocular surface disease in cataract surgery patients are

78 However, OSDI is a poor metric for capturing ocular surface disease in glaucoma because symptoms seem

79 y is a validated questionnaire that assesses ocular surface disease in the context of vision-related

80 e primary outcome was the mean change in the ocular surface disease index (0-100, higher scores indic

81 trols, at baseline, included mean scores for Ocular Surface Disease Index (31.7 vs 4.1, P < 0.0001),

82 duals with dry eye disease (DED), defined as Ocular Surface Disease Index (OSDI) >=13 and/or corneal

83 ion of patients by DED parameters including, Ocular Surface Disease Index (OSDI) (<=13, >13) and Schi

84 Symptoms of DED were assessed by Ocular Surface Disease Index (OSDI) and Brief Ocular Dis

85 ation including symptom assessment using the Ocular Surface Disease Index (OSDI) and corneal fluoresc

86 In this prospective study, based on the ocular surface disease index (OSDI) and corneal staining

87 al microscopy (IVCM) and were surveyed using Ocular Surface Disease Index (OSDI) and Glaucoma Symptom

88 LSCM, IC, and the ocular surface disease index (OSDI) and National Eye Ins

89 DED symptoms were assessed by Ocular Surface Disease Index (OSDI) and signs were asses

90 ptoms of ocular GVHD were assessed using the Ocular Surface Disease Index (OSDI) and Symptom Assessme

91 oints were ocular comfort as measured by the Ocular Surface Disease Index (OSDI) and vision-related q

92 The Ocular Surface Disease Index (OSDI) is a 12-item scale f

93 was conducted on 310 participants using the ocular surface disease index (OSDI) questionnaire and th

94 Ocular Surface Disease Index (OSDI) questionnaire scores

95 e included as objective metrics, whereas the Ocular Surface Disease Index (OSDI) questionnaire was ad

96 on of corneal fluorescein staining (CFS).The Ocular Surface Disease Index (OSDI) questionnaire was ad

97 The ocular surface disease index (OSDI) questionnaire was al

98 An interviewer-assisted Ocular Surface Disease Index (OSDI) questionnaire was us

99 e Vision Function Questionnaire (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaire were a

100 mic assessment including a detailed history, Ocular Surface Disease Index (OSDI) questionnaire, and o

101 f dry eye signs and symptoms composed of the Ocular Surface Disease Index (OSDI) questionnaire, corne

102 An assessment of DED was done with Ocular Surface Disease Index (OSDI) questionnaire, Schir

103 A subset of 689 women completed the Ocular Surface Disease Index (OSDI) questionnaire.

104 eted quality of life was evaluated using the Ocular Surface Disease Index (OSDI) questionnaire.

105 (VAS) for dry eye symptoms VAS severity, and Ocular Surface Disease Index (OSDI) questionnaire.

106 d scale and break up time, Schirmer test and Ocular Surface Disease Index (OSDI) questionnaire.

107 rity, Schirmer I, blink interval timing, and Ocular Surface Disease Index (OSDI) questionnaire.

108 ular discomfort symptoms were ascertained by ocular surface disease index (OSDI) questionnaire.

109 Patient symptoms were assessed using the Ocular Surface Disease Index (OSDI) questionnaire.

110 y, Schirmer I, blink interval timing and the Ocular Surface Disease Index (OSDI) questionnaire.

111 Participants filled in ocular surface disease index (OSDI) questionnaires.

112 ime (NIBUT), tear meniscus height (TMH), and ocular surface disease index (OSDI) results were evaluat

113 study team assessed the total MGD score and Ocular Surface Disease Index (OSDI) score at the initial

114 howed 3 of the following 4 dry eye criteria: ocular surface disease index (OSDI) score of more than 1

115 ducted to collect data on cosmetic usage and Ocular Surface Disease Index (OSDI) scores from a divers

116 uated by fluorescein breakup time (FBUT) and Ocular Surface Disease Index (OSDI) scores.

117 vere DED patients was performed according to Ocular Surface Disease Index (OSDI) scores: 32-50, 51-70

118 after PROSE fitting using Snellen acuity and Ocular Surface Disease Index (OSDI) survey.

119 Outcome variables were the Ocular Surface Disease Index (OSDI) symptom questionnair

120 Higher Ocular Surface Disease Index (OSDI) symptom scores were

121 Ocular Surface Disease Index (OSDI) symptoms score and S

122 o identify predictors for the improvement in Ocular Surface Disease Index (OSDI) was also performed.

123 al Function Questionnaire (NEI-VFQ), and the Ocular Surface Disease Index (OSDI) were included.

124 of dry eye disease (DED) as assessed by the Ocular Surface Disease Index (OSDI), a 12-item symptom f

125 Demographic information, the Ocular Surface Disease Index (OSDI), and Glaucoma Qualit

126 bum quality, meibomian gland expressability, ocular surface disease index (OSDI), and standard patien

127 symptoms and related effects as measured by Ocular Surface Disease Index (OSDI), change from baselin

128 The Ocular Surface Disease Index (OSDI), Schirmer I test (wi

129 ive dry eye outcomes with baseline including Ocular Surface Disease Index (OSDI), tear break up time

130 Outcome measures including Ocular surface disease index (OSDI), tear break-up time

131 Parameters evaluated were: Ocular Surface Disease Index (OSDI), Tear Break-Up-Time

132 c tests for dry eye disease (DED), including ocular surface disease index (OSDI), tear breakup time (

133 A symptom questionnaire, the Ocular Surface Disease Index (OSDI), was also administer

134 r break-up time (TBUT), Schirmer I test, and Ocular surface disease index (OSDI), were evaluated at b

135 ar breakup time (TBUT), tear osmolarity, and ocular surface disease index (OSDI).

136 uestionnaires at each visit to determine the Ocular Surface Disease Index (OSDI).

137 urvey included demographic questions and the Ocular Surface Disease Index (OSDI).

138 ing the 5-item Dry Eye Questionnaire and the Ocular Surface Disease Index (OSDI).

139 Symptoms were evaluated using the Ocular Surface Disease Index (OSDI).

140 isual-related function subscale score of the Ocular Surface Disease Index (VR-OSDI).

141 in (1) tear osmolarity and (2) DED symptoms (Ocular Surface Disease Index [OSDI] score) between days

142 her DE symptoms scores compared to controls (Ocular Surface Disease Index [OSDI] scores: mean 41.20 2

143 her DE symptoms scores compared to controls (Ocular Surface Disease Index [OSDI] scores: mean 41.20+/

144 ich included vision-related quality of life (Ocular Surface Disease Index [OSDI]), clinical examinati

145 Dry eye symptoms (Ocular Surface Disease Index [OSDI]), signs (tear break-

146 ision-related quality-of-life questionnaire (Ocular Surface Disease Index [OSDI]).

147 taining scores [Ora scales]) and subjective (Ocular Surface Disease Index [OSDI], 7-item visual analo

148 mptoms (5-Item Dry Eye Questionnaire [DEQ5], Ocular Surface Disease Index [OSDI], and Neuropathic Pai

149 Ocular Surface Disease Index and Functional Assessment o

150 An ocular surface disease index and lifestyle questionnaire

151 me, and corneal and ocular surface staining, Ocular Surface Disease Index and Ocular Pain Assessment

152 onjunctival staining, meibomian grading, and Ocular Surface Disease Index and SF-36v2 questionnaires

153 tudies has been in Asia since 2010, with the Ocular Surface Disease Index being the most used.

154 After 4 weeks, the Ocular Surface Disease Index decreased significantly in

155 temperature (OST) and tear production using ocular Surface Disease Index questionnaire (OSDI), OcuSe

156 t months 4, 8, 12, 18 patients underwent the Ocular Surface Disease Index questionnaire (OSDI), tear

157 estionnaire (NEI-VFQ 25); and c) the 12-item Ocular Surface Disease Index Questionnaire (OSDI).

158 The Ocular Surface Disease Index questionnaire was given to

159 viduals who had dry eye assessments included Ocular Surface Disease Index questionnaire, meibum quali

160 smometer, along with other diagnostic tests (Ocular Surface Disease Index questionnaire, Tear film br

161 ilm and ocular surface parameters, including Ocular Surface Disease Index questionnaire, visual analo

162 ant change in visual acuity, Schirmer I, and Ocular Surface Disease Index score (P > .05).

163 The mean change in ocular surface disease index score at eight weeks was -1

164 The Ocular Surface Disease Index score decreased in patients

165 and subsequent PRK enhancement, reporting an Ocular Surface Disease Index score of 100.

166 of patients with a decrease from baseline in ocular surface disease index score of at least 10 points

167 The mean ocular surface disease index score was 28.9 +/- 19.8.

168 Higher ocular surface disease index scores can be predicted by

169 articipants in the PROWL-2 study with normal Ocular Surface Disease Index scores were 44% (95% CI, 38

170 articipants in the PROWL-1 study with normal Ocular Surface Disease Index scores were 55% (95% CI, 48

171 ts have been associated with improvements in Ocular Surface Disease Index scores, a disease-specific

172 served in various indicators such as reduced Ocular Surface Disease Index scores, increased tear secr

173 Satisfaction with Correction subscales; the Ocular Surface Disease Index's (OSDI's) Symptoms subscal

174 Primary endpoints were mean IOP change and Ocular Surface Disease Index(c) (OSDI) score at each vis

175 The OSDI score (Ocular Surface Disease Index(C)) was applied in an onlin

176 inistration of a standardized questionnaire (Ocular Surface Disease Index) and a complete ophthalmolo

177 tear osmolarity (TearLab system), symptoms (Ocular Surface Disease Index), and corneal fluorescein s

178 ng, and an irritation symptom questionnaire (Ocular Surface Disease Index).

179 test, conjunctival lissamine staining score, ocular surface disease index, and individual dry eye sym

180 al rating of eye symptoms, Lee eye subscale, Ocular Surface Disease Index, and Schirmer test.

181 d in subjective symptoms (from P < 0.001 for Ocular Surface Disease Index, OSDI to p = 0.019 for tear

182 Ocular signs and symptoms (Ocular Surface Disease Index, OSDI) were assessed at day

183 or a clinical diagnosis of dry eye using the Ocular Surface Disease Index, Schirmer tear test, tear b

184 dry eye-related symptoms as measured by the Ocular Surface Disease Index, tear film breakup time, an

185 y where the residents were studied using the Ocular Surface Disease Index, together with diagnostic t

186 ere assessed using the Arabic version of the ocular surface disease index.

187 Ocular surface diseases index (OSDI) questionnaire score

188 baseline) and on postoperative day 90: MRD1, Ocular-Surface-Disease-Index (OSDI), Schirmer test 2, te

189 cycline, an agent used to treat MMP-mediated ocular surface disease, inhibited the hyperosmolarity-in

190 Except cataract surgery, all ocular surface diseases, intraocular diseases, trauma or

191 Ocular surface disease is an important risk factor for g

192 Dry eye disease (DED), a multifactorial ocular surface disease, is estimated to affect up to 34%

193 Squamous metaplasia occurs in ocular surface diseases like Sjogren's syndrome (SS).

194 Patients with ocular surface disease or dry eye syndrome were excluded

195 , yeasts were the predominant isolates, with ocular surface disease (OSD) being the leading risk fact

196 Eyes with ocular surface disease (OSD) had significantly more comp

197 of polyethylene covers in the prevention of ocular surface disease (OSD) in patients admitted to the

198 The purpose of our study was to compare Ocular Surface Disease (OSD) signs and symptoms of Taflu

199 ry eye symptoms amongst patients with severe ocular surface disease (OSD) were considered.

200 uity (VA) and side effects were divided into ocular surface disease (OSD), secondary glaucoma, or cat

201 Each patient had signs and symptoms of ocular surface disease (OSD).

202 halmologists treating glaucoma patients with ocular surface disease (OSD).

203 Ocular surface diseases (OSD) can cause serious visual d

204 ome of the interesting published research on ocular surface disease over the past year.

205 festations noted were hyperopia and signs of ocular surface disease owing to nocturnal lagophthalmos

206 drainage device (P = .023), and preexisting ocular surface disease (P = .037) were associated with r

207 utes markedly to the development of numerous ocular surface diseases, particularly dry eye disease (D

208 Autoimmune diseases and ocular surface diseases precipitate de novo glaucoma, wh

209 method capable of assisting the diagnosis of ocular surface disease, predicting the qualities of a le

210 y of Life 17 (Glau-QoL17) questionnaire, and Ocular Surface Disease Quality of Life (OSD-QoL) questio

211 ional case series performed at a corneal and ocular surface diseases referral center in 2010.

212 wo thirds of pediatric patients with chronic ocular surface disease related to SJS/TEN and results in

213 In a large cohort of patients with chronic ocular surface disease related to SJS/TEN, PROSE treatme

214 ective device for rehabilitation in advanced ocular surface disease, resulting in a significant impro

215 Clinicians who treat patients with ocular surface disease should be aware of scleral rigid

216 Ocular surface disease signs were worse in patients with

217 Patients with ocular surface disease still require extra lubrication a

218 gery to be performed in patients with severe ocular surface disease such as ocular cicatricial pemphi

219 higher rates of corneal vascularization and ocular surface disease than adults.

220 an gland damage and induces a robust form of ocular surface disease that correlates with MGD severity

221 Keratoconjunctivitis sicca is a common ocular surface disease that develops in patients with aq

222 g normal at birth, develop a chronic form of ocular surface disease that is marked by increased apopt

223 Here, we used a mouse model of ocular surface disease to reveal that commensals were pr

224 h DALK (P = .03) and PKP (P = .002), whereas ocular surface disease was a significant risk factor for

225 Ocular surface disease was observed in 78.4% of the wPBR

226 Ocular surface disease was significantly more common in

227 Eyelid laxity and ocular surface disease were assessed on bedside ophthalm

228 Microcystic epithelial changes and ocular surface disease were demonstrated biomicroscopica

229 biotechnology-based treatment agent against ocular surface diseases where endogenous lacritin is ina

230 Dry eye is a complicated ocular surface disease whose exact pathogenesis is not y

231 To treat ocular surface disease with a topical biotherapeutic, th

232 case of the patient with APS-1 presenting as ocular surface disease with NK.

233 report present advances in the treatment of ocular surface disease with scleral rigid gas-permeable

234 elevant to the clinician in the diagnosis of ocular surface diseases with an increased level of infla